Helix BioPharma Corp. faced significant losses in yesterday's trading session, reflecting investor concerns.
Helix BioPharma Corp. (HBP.TO) saw its stock price drop by 7.02% yesterday, closing at CA$1.06. This decline comes amidst ongoing uncertainty regarding the company's financial health and future prospects.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$80.96M
52W high
$5.40
52W low
$0.92
1W change
-9.40%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 135.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+135.8% Upside
Current Price
C$1.06
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
99.2%
Annualized
90-Day Vol
71.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.89
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.00 | C$0.71 – C$1.41 |
| 60 trading days | C$0.94 | C$0.58 – C$1.53 |
| 90 trading days | C$0.89 | C$0.49 – C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious about Helix BioPharma Corp. as the recent drop in stock price may signal deeper issues within the company.
7.02% drop in stock price yesterday
Helix BioPharma's market cap now stands at CA$80.96 million, reflecting investor skepticism.
Bull case
If Helix BioPharma can successfully advance its clinical studies and secure additional funding, it could recover and present growth opportunities.
Bear case
Continued financial losses and unclear communication about future plans could further erode investor confidence and lead to additional declines.
Advertisement
Recent Performance Analysis
In yesterday's trading session, Helix BioPharma Corp. fell by 7.02%, closing at CA$1.06. This decline is concerning, especially given the company's recent financial results, which reported a net loss of $5.2 million for the fiscal year ending July 31, 2025. The lack of positive news or developments has likely contributed to investor apprehension.
Market Sentiment and Future Outlook
Investor sentiment surrounding Helix BioPharma has turned negative, with many questioning the company's ability to secure funding and advance its clinical trials. The absence of recent positive announcements has left investors wary, which may lead to further declines if the company does not address these concerns. For more insights on Helix BioPharma's financial situation, check out our detailed analysis on HBP.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
